Jon E. Angell

Array ( [id] => 15898447 [patent_doc_number] => 20200148742 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-05-14 [patent_title] => EXPRESSION OF NKG2D ACTIVATING LIGAND PROTEINS FOR SENSITIZING CANCER CELLS TO ATTACK BY CYTOTOXIC IMMUNE CELLS [patent_app_type] => utility [patent_app_number] => 16/309862 [patent_app_country] => US [patent_app_date] => 2017-06-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 8127 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -35 [patent_words_short_claim] => 53 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16309862 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11979650 [patent_doc_number] => 20170283805 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-10-05 [patent_title] => 'Antisense RNA for Treating Cancer and Inhibition of Metastasis and Vectors for Antisense Sequestration' [patent_app_type] => utility [patent_app_number] => 15/620150 [patent_app_country] => US [patent_app_date] => 2017-06-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 22 [patent_figures_cnt] => 22 [patent_no_of_words] => 24523 [patent_no_of_claims] => 10 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15620150 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14391377 [patent_doc_number] => 10308959 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2019-06-04 [patent_title] => Methods, systems, and compositions relating to MiRNA-146a [patent_app_type] => utility [patent_app_number] => 15/600567 [patent_app_country] => US [patent_app_date] => 2017-05-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 27 [patent_figures_cnt] => 31 [patent_no_of_words] => 14790 [patent_no_of_claims] => 23 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 38 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15600567 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12023925 [patent_doc_number] => 20170314025 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-11-02 [patent_title] => 'MODIFIED TGF-BETA OLIGONUCLEOTIDE FOR USE IN A METHOD OF PREVENTING AND/OR TREATING AN OPHTHALMIC DISEASE' [patent_app_type] => utility [patent_app_number] => 15/593764 [patent_app_country] => US [patent_app_date] => 2017-05-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 45 [patent_figures_cnt] => 45 [patent_no_of_words] => 19360 [patent_no_of_claims] => 13 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15593764 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14743833 [patent_doc_number] => 20190255090 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-08-22 [patent_title] => EGFR GENE EXPRESSION-SUPPRESSING SIRNA, PRECURSOR OF SAME, AND APPLICATIONS THEREOF [patent_app_type] => utility [patent_app_number] => 16/099006 [patent_app_country] => US [patent_app_date] => 2017-05-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 8566 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -10 [patent_words_short_claim] => 102 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16099006 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17287213 [patent_doc_number] => 11203754 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-12-21 [patent_title] => Microrna compositions and methods of making and using same [patent_app_type] => utility [patent_app_number] => 15/581705 [patent_app_country] => US [patent_app_date] => 2017-04-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 3 [patent_figures_cnt] => 3 [patent_no_of_words] => 14306 [patent_no_of_claims] => 12 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 63 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15581705 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16876870 [patent_doc_number] => 11026990 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-06-08 [patent_title] => PUM 1 protein as target for virus inhibition [patent_app_type] => utility [patent_app_number] => 16/477406 [patent_app_country] => US [patent_app_date] => 2017-04-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 5 [patent_figures_cnt] => 5 [patent_no_of_words] => 9118 [patent_no_of_claims] => 13 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 60 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16477406 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11971471 [patent_doc_number] => 20170275625 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-09-28 [patent_title] => 'Methods Of Inhibiting Tumorigenesis In Colon Adenocarcinoma And Compositions Therefor' [patent_app_type] => utility [patent_app_number] => 15/484446 [patent_app_country] => US [patent_app_date] => 2017-04-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 26 [patent_figures_cnt] => 26 [patent_no_of_words] => 39155 [patent_no_of_claims] => 8 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15484446 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14360681 [patent_doc_number] => 10301628 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2019-05-28 [patent_title] => Treatment of idiopathic pulmonary fibrosis using RNA complexes that target connective tissue growth factor [patent_app_type] => utility [patent_app_number] => 15/483305 [patent_app_country] => US [patent_app_date] => 2017-04-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 15 [patent_figures_cnt] => 15 [patent_no_of_words] => 9519 [patent_no_of_claims] => 12 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 83 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15483305 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12858040 [patent_doc_number] => 20180177854 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-06-28 [patent_title] => MICRO-RNA-155 ENHANCES THE EFFICACY OF DENDRITIC CELL VACCINE FOR CANCER [patent_app_type] => utility [patent_app_number] => 15/477245 [patent_app_country] => US [patent_app_date] => 2017-04-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 10083 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -13 [patent_words_short_claim] => 66 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15477245 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11954786 [patent_doc_number] => 20170258938 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-09-14 [patent_title] => 'EXOSOME TRANSFER OF NUCLEIC ACIDS TO CELLS' [patent_app_type] => utility [patent_app_number] => 15/476844 [patent_app_country] => US [patent_app_date] => 2017-03-31 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 5020 [patent_no_of_claims] => 11 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15476844 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13703285 [patent_doc_number] => 20170362597 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-12-21 [patent_title] => EGFR NUCLEIC ACIDS AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 15/476117 [patent_app_country] => US [patent_app_date] => 2017-03-31 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 28646 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -31 [patent_words_short_claim] => 31 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15476117 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12023931 [patent_doc_number] => 20170314030 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-11-02 [patent_title] => 'BETA-CATENIN NUCLEIC ACIDS AND USES THEREOF' [patent_app_type] => utility [patent_app_number] => 15/476341 [patent_app_country] => US [patent_app_date] => 2017-03-31 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 20343 [patent_no_of_claims] => 33 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15476341 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16413251 [patent_doc_number] => 10821112 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-11-03 [patent_title] => Compositions and methods for the treatment of a beta-catenin-associated disease or disorder [patent_app_type] => utility [patent_app_number] => 16/084852 [patent_app_country] => US [patent_app_date] => 2017-03-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 20 [patent_figures_cnt] => 28 [patent_no_of_words] => 12683 [patent_no_of_claims] => 23 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 85 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16084852 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16141961 [patent_doc_number] => 10704045 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-07-07 [patent_title] => Methods and compositions for increased double stranded RNA production [patent_app_type] => utility [patent_app_number] => 16/084545 [patent_app_country] => US [patent_app_date] => 2017-03-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 6 [patent_figures_cnt] => 6 [patent_no_of_words] => 11866 [patent_no_of_claims] => 33 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 158 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16084545 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14102799 [patent_doc_number] => 20190093075 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-03-28 [patent_title] => METHODS AND COMPOSITIONS FOR EX VIVO EXPANSION OF VERY SMALL EMBRYONIC-LIKE STEM CELLS (VSELS) [patent_app_type] => utility [patent_app_number] => 16/081665 [patent_app_country] => US [patent_app_date] => 2017-03-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 18063 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -45 [patent_words_short_claim] => 62 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16081665 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16492626 [patent_doc_number] => 10858653 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-12-08 [patent_title] => Mammalian cells for producing a secreted protein [patent_app_type] => utility [patent_app_number] => 16/083982 [patent_app_country] => US [patent_app_date] => 2017-02-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 20 [patent_figures_cnt] => 40 [patent_no_of_words] => 30482 [patent_no_of_claims] => 6 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 60 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16083982 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13926071 [patent_doc_number] => 20190046551 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-02-14 [patent_title] => PHARMACEUTICAL COMPOSITION FOR TREATING AND/OR PREVENTING CANCER [patent_app_type] => utility [patent_app_number] => 16/073244 [patent_app_country] => US [patent_app_date] => 2017-01-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 12457 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -13 [patent_words_short_claim] => 69 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16073244 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13154419 [patent_doc_number] => 10093924 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2018-10-09 [patent_title] => Multimetric oligonucleotide compounds [patent_app_type] => utility [patent_app_number] => 15/416100 [patent_app_country] => US [patent_app_date] => 2017-01-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 45 [patent_figures_cnt] => 57 [patent_no_of_words] => 32175 [patent_no_of_claims] => 22 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 170 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15416100 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17163179 [patent_doc_number] => 11149268 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-10-19 [patent_title] => Assembly system for a eukaryotic cell [patent_app_type] => utility [patent_app_number] => 16/319746 [patent_app_country] => US [patent_app_date] => 2016-12-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 36 [patent_figures_cnt] => 44 [patent_no_of_words] => 52062 [patent_no_of_claims] => 13 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 234 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16319746 [rel_patent_id] =>[rel_patent_doc_number] =>)